Skip to content

JBIO JBIO Other income, net (Note 6)

Other income, net (Note 6) at other companies

Travere Therapeutics, Inc. logo
Travere Therapeutics, Inc.TVTX
-$91K-117%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
-$1K-100%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
-$62K+27.1%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
-$336K-226%
Alumis Inc. logo
Alumis Inc.ALMS
$7K+116%
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX

Other financials

Income statement

See full
Operating income-$43.4M-85.8%
Net income-$40.4M-5.8%
EPS (diluted)-$0.57+95.3%

Balance sheet

See full
Cash & equivalents$55.1M+24.6%
Total debt$808.0K+159%
Total equity$296.5M+455%
Total assets$319.4M+312%

Cash flow

See full
Operating cash flow-$24.1M-28.4%
CapEx$3.0K
Free cash flow-$33.7M

Valuation

See full
Market cap$1.33B+318%
Enterprise value$1.28B

Returns & leverage

See full
Return on equity-132.5%+120pp
Debt / equity
Current ratio14.3×-17.7×

Where this comes from

Reported directly by JBIO in its filing.

Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.

The official record: JBIO’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about JBIO's other income, net (note 6).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is JBIO's other income, net (note 6)?
JBIO (JBIO) reported other income, net (note 6) of -$9K in Q1 2026.
What is the long-term trend for JBIO's other income, net (note 6)?
Over 3 years (2021 to 2024), JBIO's other income, net (note 6) has grown at a 158.8% compound annual growth rate (CAGR), from $80K to $1.39M.
What does other income, net (note 6) mean?
This captures miscellaneous financial items that fall outside the scope of core operating activities, such as foreign exchange gains or losses, minor investment income, or non-recurring legal settlements. It serves as a catch-all for peripheral financial events that do not stem from the primary business operations. Investors monitor this to isolate core earnings from transient or incidental financial fluctuations.